Eradication of prior-to-treatment compound BCR-ABL mutations by interferon-alpha in chronic myeloid leukemia: Long-term follow-up studies and review of literature

Eradication of prior-to-treatment compound BCR-ABL mutations by interferon-alpha in chronic myeloid leukemia: Long-term follow-up studies and review of literature

BACKGROUND: Although tyrosine kinase inhibitors (TKIs) are the gold standard in clinical management of chronic myeloid leukemia, it is not feasible to use these drugs in at least some cases when patients are resistance to all available TKIs due to compound BCR-ABL mutations, due to patient safety pr...

Full description

Bibliographic Details
Main Authors: Zafar Iqbal, Tanveer Akhtar, Ahmad M Khalid, Aamer Aleem, Amer Mahmood, Afia M Akram, Mahmood Rasool, Ijaz H Shah, Aysha Bhalli, Muhammad Khalid, Mudassar Iqbal, Abid Jameel, Nawaf Al-Anazi
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2020-01-01
Series:Journal of Applied Hematology
Subjects:
chronic myeloid leukemia
compound bcr-abl mutations
interferon
pan-tyrosine kinase inhibitor resistance
ponatinib resistance
Online Access:http://www.jahjournal.org/article.asp?issn=1658-5127;year=2020;volume=11;issue=3;spage=108;epage=111;aulast=Iqbal

Internet

http://www.jahjournal.org/article.asp?issn=1658-5127;year=2020;volume=11;issue=3;spage=108;epage=111;aulast=Iqbal

Similar Items